ERBB2 and breast neoplasm: QUESTION: Can PET/CT assess [89Zr]Zr-oxine–labeled human NK cell infiltration in HER2-positive breast tumors and quantify whether HER2-targeted trastuzumab therapy enhances this infiltration?